CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2017--
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host
its fourth quarter and full-year 2016 investor update conference call
and webcast at 4:30 p.m. Eastern Time on Tuesday, February 21, 2017.
Individuals interested in participating in the call should dial (877)
643-7155 (U.S. and Canada) or (914) 495-8552 (international)
using conference ID number 59788100. To access the webcast, please visit
the Investors section of Ironwood’s website at www.ironwoodpharma.com
at least 15 minutes prior to the start of the call to ensure adequate
time for any software downloads that may be required.
The call will be available for replay via telephone starting February
21, 2017 at approximately 7:30 p.m. Eastern Time, running through 11:59
p.m. Eastern Time on February 28, 2017. To listen to the replay, dial
(855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using
conference ID number 59788100. The archived webcast will be available on
Ironwood’s website for 14 days beginning approximately one hour after
the call has completed.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology
company focused on creating medicines that make a difference for
patients, building value for our fellow shareholders, and empowering our
passionate team. We are commercializing two innovative primary care
products: linaclotide, the U.S. branded prescription market leader for
adults with irritable bowel syndrome with constipation (IBS-C) or
chronic idiopathic constipation (CIC), and lesinurad, which is approved
to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of
hyperuricemia associated with uncontrolled gout. We are also advancing a
pipeline of internally and externally generated innovative product
candidates in areas of significant unmet need, including uncontrolled
gastroesophageal reflux disease and vascular and fibrotic diseases.
Ironwood was founded in 1998 and is headquartered in Cambridge,
Mass. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma;
information that may be important to investors will be routinely posted
in both these locations.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170207006429/en/
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc.
Director, Corporate Communications
Meredith Kaya, 617-374-5082